Literature DB >> 28595078

Amyloidogenic proteins associated with neurodegenerative diseases activate the NLRP3 inflammasome.

Qian-Hang Shao1, Xiao-Ling Zhang1, Peng-Fei Yang1, Yu-He Yuan2, Nai-Hong Chen3.   

Abstract

Neuroinflammation has been shown as an essential factor in the pathogenesis of neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, and Multiple Sclerosis. Furthermore, activated microglia and increased pro-inflammatory cytokines are the major hallmarks in neurodegenerative diseases. A multimolecular complex named as inflammasome is involved in the process of inflammatory response, which can activate inflammatory caspases, leading to the cleavage and secretion of inflammatory cytokines, and finally generates a potent inflammatory response. In neurodegenerative diseases, it has been widely assumed that some types of amyloid proteins might be the triggers to activate the NLRP3 inflammasome. In this review, we summarize the current researches about the role of NLRP3 inflammasome, by reviewing the main studies in vitro and in vivo experiments and discuss the potential for new therapeutic interventions in neurodegenerative diseases.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amyloid-β; Inflammation; NLRP3 inflammasome; Neurodegenerative disease; α-Synuclein

Mesh:

Substances:

Year:  2017        PMID: 28595078     DOI: 10.1016/j.intimp.2017.05.027

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  9 in total

1.  IL-4 and IL-10 promotes phagocytic activity of microglia by up-regulation of TREM2.

Authors:  Saini Yi; Xue Jiang; Xiaofang Tang; Yahui Li; Chenghong Xiao; Jinqiang Zhang; Tao Zhou
Journal:  Cytotechnology       Date:  2020-07-04       Impact factor: 2.058

2.  Single-Cell Sequencing Analysis of the db/db Mouse Hippocampus Reveals Cell-Type-Specific Insights Into the Pathobiology of Diabetes-Associated Cognitive Dysfunction.

Authors:  Shizhan Ma; Wenkai Bi; Xueying Liu; Shangbin Li; Yaxin Qiu; Chengcheng Huang; Renjun Lv; Qingqing Yin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-01       Impact factor: 6.055

3.  NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP.

Authors:  Ying Chen; Qiu-Shuang Zhang; Qian-Hang Shao; Shuo Wang; Yu-He Yuan; Nai-Hong Chen; Hong-Bo Wang
Journal:  Acta Pharmacol Sin       Date:  2019-02-06       Impact factor: 6.150

4.  Notoginsenoside R1 ameliorates diabetic encephalopathy by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation.

Authors:  Yadong Zhai; Xiangbao Meng; Yun Luo; Yongmei Wu; Tianyuan Ye; Ping Zhou; Shilan Ding; Min Wang; Senbao Lu; Lili Zhu; Guibo Sun; Xiaobo Sun
Journal:  Oncotarget       Date:  2018-01-16

Review 5.  Targeting NLRP3 Inflammasome in the Treatment of CNS Diseases.

Authors:  Bo-Zong Shao; Qi Cao; Chong Liu
Journal:  Front Mol Neurosci       Date:  2018-09-04       Impact factor: 5.639

6.  NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson's disease.

Authors:  Katharine M von Herrmann; Lucas A Salas; Eileen M Martinez; Alison L Young; Joseph M Howard; Mary S Feldman; Brock C Christensen; Owen M Wilkins; Stephen L Lee; William F Hickey; Matthew C Havrda
Journal:  NPJ Parkinsons Dis       Date:  2018-08-15

Review 7.  Oral Dysbiosis and Neurodegenerative Diseases: Correlations and Potential Causations.

Authors:  Justine S Nicholson; Kyle S Landry
Journal:  Microorganisms       Date:  2022-06-30

Review 8.  The Significance of NLRP Inflammasome in Neuropsychiatric Disorders.

Authors:  Yao Shen; Liyin Qian; Hu Luo; Xiaofang Li; Yuer Ruan; Runyue Fan; Zizhen Si; Yunpeng Chen; Longhui Li; Yu Liu
Journal:  Brain Sci       Date:  2022-08-10

9.  Brain Microbiota in Huntington's Disease Patients.

Authors:  Ruth Alonso; Diana Pisa; Luis Carrasco
Journal:  Front Microbiol       Date:  2019-11-12       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.